A Clinicopathological Phase II Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas.

Trial Profile

A Clinicopathological Phase II Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Axitinib (Primary)
  • Indications Haemangiosarcoma; Kaposi's sarcoma; Leiomyosarcoma; Soft tissue sarcoma
  • Focus Therapeutic Use
  • Acronyms Axi-STS
  • Most Recent Events

    • 04 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 02 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
    • 11 Feb 2016 Accrual to date is 100% according to the United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top